Manuela Valente Sells 2,376 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Manuela Valente sold 2,376 shares on April 7 at an average price of $4.87 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity, trimming her stake by 1.07% to 219,275 shares (≈$1.07M).
• SOPHiA GENETICS stock traded around $4.89 (down 0.3%) with a market cap of ≈$334.6M; the company reported quarterly EPS of -$0.28 (missed consensus) and revenue of $21.71M (slightly above estimates), and remains unprofitable with negative margins.
• Institutional activity has picked up—most notably UBS Asset Management boosted its position to 7.63M shares—and analysts hold a mixed view with a consensus target of $7.00 (two Buys, one Sell).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total value of $11,571.12. Following the completion of the sale, the insider owned 219,275 shares in the company, valued at approximately $1,067,869.25. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 6th, Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $12,595.45.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $1,820.20.

SOPHiA GENETICS Trading Down 0.3%

Shares of SOPH stock traded down $0.01 during trading hours on Wednesday, reaching $4.89. The company's stock had a trading volume of 64,929 shares, compared to its average volume of 188,371. The stock has a market capitalization of $334.64 million, a P/E ratio of -9.58 and a beta of 1.04. SOPHiA GENETICS SA has a one year low of $2.58 and a one year high of $5.70. The firm's fifty day simple moving average is $4.78 and its 200 day simple moving average is $4.68. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The business had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Equities research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its holdings in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS in the third quarter worth $6,708,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS in the fourth quarter worth $2,009,000. Finally, 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS in the fourth quarter worth $973,000. 31.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on SOPH. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim lifted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Finally, BTIG Research restated a "buy" rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.